- Home
- PATH vs MDGL Comparison
PATH vs MDGL Comparison
Compare PATH & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PATH
- MDGL
- Stock Information
- Founded
- PATH 2005
- MDGL 2011
- Country
- PATH United States
- MDGL United States
- Employees
- PATH N/A
- MDGL N/A
- Industry
- PATH Computer Software: Prepackaged Software
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- PATH Technology
- MDGL Health Care
- Exchange
- PATH Nasdaq
- MDGL Nasdaq
- Market Cap
- PATH 6.5B
- MDGL 6.1B
- IPO Year
- PATH 2021
- MDGL N/A
- Fundamental
- Price
- PATH $12.80
- MDGL $304.86
- Analyst Decision
- PATH Hold
- MDGL Strong Buy
- Analyst Count
- PATH 18
- MDGL 9
- Target Price
- PATH $13.97
- MDGL $420.63
- AVG Volume (30 Days)
- PATH 10.2M
- MDGL 305.4K
- Earning Date
- PATH 05-29-2025
- MDGL 08-06-2025
- Dividend Yield
- PATH N/A
- MDGL N/A
- EPS Growth
- PATH N/A
- MDGL N/A
- EPS
- PATH N/A
- MDGL N/A
- Revenue
- PATH $1,451,176,000.00
- MDGL $317,383,000.00
- Revenue This Year
- PATH $10.73
- MDGL $286.17
- Revenue Next Year
- PATH $8.46
- MDGL $64.17
- P/E Ratio
- PATH N/A
- MDGL N/A
- Revenue Growth
- PATH 7.21
- MDGL N/A
- 52 Week Low
- PATH $9.38
- MDGL $200.63
- 52 Week High
- PATH $15.93
- MDGL $377.46
- Technical
- Relative Strength Index (RSI)
- PATH 54.66
- MDGL 61.70
- Support Level
- PATH $12.25
- MDGL $277.64
- Resistance Level
- PATH $12.88
- MDGL $314.22
- Average True Range (ATR)
- PATH 0.34
- MDGL 11.62
- MACD
- PATH -0.01
- MDGL 3.11
- Stochastic Oscillator
- PATH 58.31
- MDGL 82.64
About PATH UiPath Inc.
UiPath Inc offers an end-to-end cross-application enterprise automation platform principally with computer vision technology and user interface automations in its initial RPA offering, which remains the foundation of the platform. The platform leverages a range of automation technologies including robotic process automation, application programming interface, and artificial intelligence. UiPath's solution can automate a broad range of repetitive tasks across industries including claims processing, employee onboarding, invoice to cash, loan applications, and customer service.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.